

Cerep receives approval from Chinese authorities to establish a subsidiary in China and officially opens its Shanghai laboratories

Paris, April 26, 2010 – press release 2010/06

ALCER
LISTED
NYSE
ALTERNEXT

Code ISIN FR0004042232
NYSE Alternext Paris

Cerep SA
155 boulevard Haussmann
75008 Paris (France)
tel + 33 (0)1 45 64 44 60
fax +33 (0)1 45 64 44 64
e-mail: fincom@cerep.fr
www.cerep.com

Focussing on *in vitro* pharmacology and ADME-Tox, Cerep [Nyse Alternext – ALCER] provides solutions allowing cost-effective drug discovery by identifying at early stages the most promising drug candidates and eliminating compounds likely to fail in development. Cerep's technologies benefit to more than 460 pharmaceutical and biotechnological companies worldwide including most of the top pharmaceutical firms.

Statements included in this press release which are not historical in nature are intended to be, and are hereby identified as, "forward-looking statements" for purposes of the safe harbor provided by Section 21E of the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The company cautions readers that forward-looking statements, including without limitation those relating to the company's future operations and business prospects, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements. Factors that may affect future operations and business prospects include, but are not limited to, clinical and scientific results and developments concerning corporate collaborations and the company's proprietary rights and other factors described in the company's Document de référence.

In March 2010, Cerep was granted, on behalf of its Chinese subsidiary Cerep Limited, the necessary Business License to operate in China.

The Company immediately launched its Asian operations, based in Shanghai, and successfully completed there its first pilot study. Through a panel of 71 kinase assays performed in parallel in Cerep's French and Shanghai laboratories, the Company has demonstrated the homogeneity and quality of data obtained on the new platform. The objective of this first pilot was to validate that the technical fittings at the new site were capable of achieving quality levels equivalent to Cerep's main laboratories, and therefore that the Company could now deliver to clients an equivalent level of services from its French, North American or Chinese operational facilities.

The laboratories, covering approximately 800m², were refitted over the past 6 months to rigorously comply with Cerep's quality norms and operational standards.

They are located at the heart of a first rate technology park in which a large number of high tech companies, as well as many pharmaceutical companies, have already established themselves.

Cerep is proud to be the first western laboratory establishing in China to operate an *in vitro* pharmacology platform dedicated to drug discovery.

The Group considers that setting up operations in this region was essential to better serve both Chinese companies as well as the subsidiaries of international groups operating in China. This gives Cerep a significant advantage in gaining entrance to new markets by meeting client needs where they originate, thus further developing the "satellite" strategy it started in 2009.

Cerep also considers that the growth of drug discovery outsourcing in China will intensify in the coming years, with the development of new Chinese players operating in this domain and the sustained growth of the Chinese operations of the world's leading pharmaceutical companies.

■ Contact

Thierry Jean, Chairman & CEO
Sophie Macault, General Counsel & Corporate Secretary
Michèle Arnoe, Global Head Business development
Tel. +33 (0)1 45 64 44 60
fincom@cerep.fr